CD276 and neoplasm: To model the heterogenous expression of GPC2 and CD276, which can result in tumor evasion in single-target CAR T cell therapies, we used a mixture of NALM6 cells stably expressing either GPC2 or CD276 and treated them with BiCisCARs or single antigen–targeting CARs (Figure 9A and Supplemental Figure 11A).